Literature DB >> 28966720

Confidence intervals for the difference of median failure times applied to censored tumor growth delay data.

Jianrong Wu1.   

Abstract

In tumor xenograft experiments, tumor response to the anti-cancer agents is often assessed by tumor growth delay, the difference in median tumor quadrupling times between treatment and control. Tumor quadrupling time is often subjected to right censoring because death of the experimental mice or limitations of the follow-up period. In the literature, tumor growth delay is simply reported without a standard error or confidence interval being given, which ignores the noise in the experimental data. Here, we present seven confidence intervals for the difference of medians in a general right-censored failure time framework. Simulation studies are conducted to compare the coverage probability of these intervals for small samples. The proposed intervals are applied to tumor growth delay data from an actual tumor xenograft experiment.

Entities:  

Keywords:  Bootstrap; Confidence interval; Density estimation; Right censoring; Tumor growth delay

Year:  2012        PMID: 28966720      PMCID: PMC5621763          DOI: 10.1198/sbr.2011.10020

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  7 in total

Review 1.  Tumor models for efficacy determination.

Authors:  Beverly A Teicher
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

2.  The pediatric preclinical testing program: description of models and early testing results.

Authors:  Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; C Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2007-12       Impact factor: 3.167

3.  Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

Authors:  J Thompson; E O George; C A Poquette; P J Cheshire; L B Richmond; S S de Graaf; M Ma; C F Stewart; P J Houghton
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

4.  Nonparametric estimation for the difference or ratio of median failure times.

Authors:  J Q Su; L J Wei
Journal:  Biometrics       Date:  1993-06       Impact factor: 2.571

5.  Assessing cytotoxic treatment effects in preclinical tumor xenograft models.

Authors:  Jianrong Wu; Peter J Houghton
Journal:  J Biopharm Stat       Date:  2009-09       Impact factor: 1.051

6.  Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.

Authors:  Thomas H Corbett; Kathryn White; Lisa Polin; Juiwanna Kushner; Jennifer Paluch; Chuan Shih; Cora Sue Grossman
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

7.  Methods for analysis of censored tumor growth delay data.

Authors:  M Stuschke; V Budach; M Bamberg; W Budach
Journal:  Radiat Res       Date:  1990-05       Impact factor: 2.841

  7 in total
  1 in total

1.  Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment Trials.

Authors:  Isabelle R Weir; Sean Wasserman
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.